BioTuesdays

Tag - Jason McCarthy

Cassava Sciences
Markets

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

January 10, 2020
Adamis Pharma
Markets

Maxim cuts Adamis Pharma to hold; withdraws PT

Maxim Group downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “hold” from “buy” and withdrew its previous $3 price target after the company received a complete response letter (CRL) from the FDA regarding the NDA for...

November 25, 2019
SELLAS Life Sciences
Markets

Maxim ups SELLAS to buy; sets PT $12

Maxim Group upgraded SELLAS Life Sciences (NASDAQ:SLS) to “buy” from “hold” with a price target of $12 after the company removed a financing overhang. The stock closed at $6.17 on Nov. 14. SELLAS ended the latest...

November 15, 2019
INmune Bio
Markets

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

March 19, 2019
Markets

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6.

March 6, 2018

Subscribe

Sign up to our weekly BioTuesdays newsletter.